IP Library › Granted Patent US 10,653,796
Granted Patent B2
US 10,653,796 · App. 15/769,630 · Granted May 19, 2020

Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules

Inventors: Philipp Uhl (Heidleberg, DE); Max Sauter (Heidleberg, DE); Uwe Haberkorn (Schwetzingen, DE); Walter Mier (Bensheim, DE); Gert Fricker (Dossenheim, DE)
Assignee: Universität Heidelberg
A61K47/6911A61K9/0053A61K9/10A61K9/1271A61K9/19A61K38/08A61K38/10A61K38/14A61K47/26A61K47/42A61K47/544A61K47/554A61K47/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,653,796
App. No.
15/769,630
Granted
May 19, 2020
Kind
B2
Abstract

The present invention relates to liposomal compositions, comprising liposomes comprising tetraether lipids (TELs) and cell penetrating peptides (CPPs), wherein said CPPs are attached to a compound being part of the liposome's lipid double layer. The present invention further relates to uses thereof for the oral delivery of therapeutic and/or diagnostic agents.

Claims (17)

1. A liposomal oral composition comprising liposomes, said liposomes comprising:

(a) tetraether lipids (TELs), wherein the TEL is selected from the group consisting of glycerylcaldityltetraether (GCTE) and diglyceryltetraether (DGTE) comprising an average number of four to six cyclopentyl rings and TELs comprising three to five pentyl rings, and combinations thereof;

(b) cell penetrating peptides (CPPs),

wherein said CPPs are attached to a lipid of the liposome's lipid double layer, and wherein the liposomes have a positive zeta potential and;

(c) a therapeutic and/or diagnostic agent selected from the group consisting of peptidic macromolecules, proteins and antibodies.

2. The liposomal composition according to claim 1 , wherein said TELs are derived from Sulfolobus sp.

3. The liposomal composition according to claim 2 , wherein said TELs are derived from Sulfolobus acidocaldarius.

4. The liposomal composition according to claim 1 , wherein said liposomes comprise said TELs in an amount of 1 to 10 mol-% based on the total lipid amount.

5. The liposomal composition according to claim 1 , wherein said CPPs are selected from the group consisting of linear or cyclized penetratin (SEQ ID NO: 1), TAT (transactivator of transcription)-peptide (SEQ ID NO: 2), MAP (model amphipathic peptide) (SEQ ID NO: 3), R9 (SEQ ID NO: 4), pVEC (SEQ ID NO: 5), transportan (SEQ ID NO: 6), and MPG (SEQ ID NO: 7), combinations thereof, and dimers thereof.

6. The liposomal composition according to claim 1 , wherein said liposomes comprise said CPPs in an amount of 0.1 to 1 mol-% based on the total lipid amount.

7. The liposomal composition according to claim 1 , wherein said compound to which said CPPs are attached is selected from the group consisting of cholesterol and derivatives thereof, phospholipids, lysophospholipids, and tetraetherlipids.

8. The liposomal composition according to claim 1 , wherein said CPPs are covalently attached.

9. The liposomal composition according to claim 1 , wherein said CPPs are attached via a linker.

10. The liposomal composition according to claim 9 , wherein said linker is selected from the group consisting of bifunctional PEG-linkers.

11. The liposomal composition of claim 1 , wherein the zeta potential is at least 0.068 mV.

12. The liposomal composition of claim 1 , wherein the CPPs are cyclized.

13. The liposomal composition of claim 1 , wherein the liposomes have a polydispersity index of at most 0.3.

Priority Claims (1)
EP 15003011 · Oct 21, 2015 · regional
Continuity (1)
Related Publication 20180303956A1 · Oct 25, 2018